美罗华联合地塞米松治疗难治性特发性血小板减少性紫癜的临床效果分析

Clinical Analysis of Rituximab Combined with Dexamethasone in the Treatment of Refractory Idiopathic Thrombocytopenic Purpura

目的研究美罗华联合地塞米松治疗难治性特发性血小板减少性紫癜的临床效果。方法随机选取52例于2017年7月—2018年7月被该院所收治患有难治性特发性血小板减少性紫癜患者加以研究,入选病患以自愿的原则分为两组,即研究组与对照组,对照组患者运用大剂量地塞米松加以治疗,而研究组患者则给予美罗华联合小剂量地塞米松治疗法展开治疗,比较两组患者的临床治疗情况。结果对比两组患者的治疗效果,研究组治疗总有效率为65.38%,远高于对照组的38.46%,差异有统计学意义(χ^2=4.171,P<0.05)。研究组不良反应率为26.92%,对照组为57.69%,差异有统计学意义(χ^2=5.587,P<0.05)。结论美罗华联合小剂量地塞米松运用于难治性特发性血小板减少性紫癜患者的治疗中可以有效改善临床症状,提升治疗效果,同时还能控制不良反应的产生率,具有临床推广价值。

Objective To study the clinical effect of rituximab combined with dexamethasone in the treatment of refractory idiopathic thrombocytopenic purpura.Methods A total of 52 patients were randomly selected from July 2017 to July 2018 for treatment of patients with refractory idiopathic thrombocytopenic purpura.The selected patients were divided into two groups on a voluntary basis.That is,the study group and the control group,the control group patients were treated with high-dose dexamethasone,and the patients in the study group were treated with rituximab combined with low-dose dexamethasone treatment,and the clinical treatment of the two groups was compared.Results The total effective rate of the study group was 65.38%,which was much higher than that of the control group(38.46%).The difference was statistically significant(χ^2=4.171,P<0.05).The adrerse reaction rate of the study group was 26.92%,and that of the control group was 57.69%.The difference was statistically significant.the difference was statistically significant(χ^2=5.587,P<0.05).Conclusion The combination of rituximab and low-dose dexamethasone in the treatment of refractory idiopathic thrombocytopenic purpura can effectively improve clinical symptoms,improve the therapeutic effect,and control the incidence of adverse reactons.